End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.7 USD | -3.47% | +4.38% | +53.82% |
13/06 | Employer coverage for weight-loss drugs rises sharply, survey finds | RE |
12/06 | Eli Lilly Gets FDA Approval for Selpercatinib to Treat Thyroid Cancer | MT |
Sales 2024 * | 42.98B 3,590B | Sales 2025 * | 52.62B 4,396B | Capitalization | 795B 66,437B |
---|---|---|---|---|---|
Net income 2024 * | 11.93B 997B | Net income 2025 * | 16.55B 1,383B | EV / Sales 2024 * | 18.9 x |
Net Debt 2024 * | 18.07B 1,509B | Net Debt 2025 * | 15B 1,253B | EV / Sales 2025 * | 15.4 x |
P/E ratio 2024 * |
66.1
x | P/E ratio 2025 * |
47.5
x | Employees | 43,000 |
Yield 2024 * |
0.59% | Yield 2025 * |
0.68% | Free-Float | 99.8% |
Latest transcript on Eli Lilly and Company
1 day | -3.47% | ||
1 week | +4.38% | ||
Current month | +5.03% | ||
1 month | +8.79% | ||
3 months | +5.70% | ||
6 months | +52.81% | ||
Current year | +53.82% |
Managers | Title | Age | Since |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/96/01 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16/23/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 25/21/25 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01/09/01 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01/05/01 |
Date | Price | Change | Volume |
---|---|---|---|
13/24/13 | 16.7 | -3.47% | 130 |
12/24/12 | 17.3 | +4.85% | 54 |
11/24/11 | 16.5 | +3.12% | 192 |
10/24/10 | 16 | +1.27% | 149 |
07/24/07 | 15.8 | -1.25% | 77 |
End-of-day quote Buenos Aires S.E., June 13, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.20% | 350B | |
+18.67% | 330B | |
+7.48% | 293B | |
+16.91% | 248B | |
+0.53% | 221B | |
+11.06% | 217B | |
+3.64% | 162B | |
-3.96% | 157B | |
-2.04% | 121B |
- Stock Market
- Equities
- LLY Stock
- LLYD Stock